journal article·2019-12-04Open access

Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles

Fan Li, Yuqin Wen, Yan Zhang, Kangyu Zheng, Junfeng Ban, Qingchun Xie, Yifeng Wen, Qing Liu, Fohua Chen, Zhenjie Mo, Lizhong Liu, Yanzhong Chen, Zhufen Lu

Abstract

Aim: 2-HP-β-cyclodextrin-PLGA nanoparticle complexes were prepared to enhance the aqueous humour delivery of Triamcinolone acetonide.Materials & methods: Drug-loaded 2-HP-β-CD/PLGA nanoparticle complexes prepared by adapting a quasi-emulsion solvent evaporation technique. In vitro drug release, in vitro transcorneal permeation study, histopathological study and in vivo transcorneal penetration of PLGA nanoparticles and 2-HP-β-CD/PLGA nanoparticle complexes were evaluated. Results: Particle size distributions of 2-HP-β-CD/PLGA nanoparticle complexes were 149.4 ± 3.7 nm and presented stable system. Corneal penetration studies revealed steady sustained drug release (First-order); 2-HP-β-CD/PLGA nanoparticle complexes increased ocular bioavailability by increasing dispersion in the tear film and improving drug release. Conclusion: 2-HP-β-CD/PLGA nanoparticle complex formulation is a promising alternative to conventional eye drops.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University

Guangdong Provincial Engineering Center of Topical Precise Drug Delivery Systems, Guangdong Pharmaceutical University

R&D Team for Formulation Innovation, Guangdong Pharmaceutical University

Department of Hospital Pharmacy, Ningbo 7 Hospital

Funding

R&D Team for Formulation Innovation · Guangdong Pharmaceutical University · Guangdong “Climbing” Programme

References (46)

Show source-provided references
1. 10.2217/nnm-2017-031810.2217/nnm-2017-0318 ↗
2. 10.2147/IJN.S12619910.2147/IJN.S126199 ↗
3. 10.1016/j.clae.2017.06.00310.1016/j.clae.2017.06.003 ↗
4. 10.4103/2231-4040.14302210.4103/2231-4040.143022 ↗
5. 10.4103/tjo.tjo_75_1710.4103/tjo.tjo_75_17 ↗
6. 10.3109/10837450.2015.112592210.3109/10837450.2015.1125922 ↗
7. 10.1016/j.jconrel.2018.06.03110.1016/j.jconrel.2018.06.031 ↗
8. 10.1007/s11095-017-2319-810.1007/s11095-017-2319-8 ↗
9. 10.1016/j.biopha.2017.07.11010.1016/j.biopha.2017.07.110 ↗
10. 10.1016/j.nano.2009.10.00410.1016/j.nano.2009.10.004 ↗
11. 10.1002/jbm.a.3544610.1002/jbm.a.35446 ↗
12. 10.1208/s12249-017-0710-810.1208/s12249-017-0710-8 ↗
13. 10.1093/protein/gzg13710.1093/protein/gzg137 ↗
14. 10.2147/IJN.S2848110.2147/IJN.S28481 ↗
15. 10.2174/138161282266616121611320710.2174/1381612822666161216113207 ↗
16. 10.3109/10837450.2012.70529810.3109/10837450.2012.705298 ↗
17. Huang X. Preparation and preliminary study of targeting of cyclodextrin coated PLGA nanoparticles [master’s thesis]. Guangzhou: Guangdong Pharmaceutical University; 2018.
18. 10.1016/0032-3861(81)90230-510.1016/0032-3861(81)90230-5 ↗
19. 10.1002/pen.76023120410.1002/pen.760231204 ↗
20. 10.1007/s10973-011-1299-x10.1007/s10973-011-1299-x ↗
21. 10.1007/s10792-018-0955-610.1007/s10792-018-0955-6 ↗
22. Macri A, Marini V, Sangalli G, et al. An artificial aqueous humor as a standard matrix to assess drug concentration in the anterior chamber by high performance liquid chromatography methods. Clin Lab. 2015;61(1–2):47–52.
23. 10.1080/0271368059093409410.1080/02713680590934094 ↗
24. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol. 1997;35(9):941–947.
25. 10.1016/S0039-6257(01)00211-910.1016/S0039-6257(01)00211-9 ↗
26. 10.1093/bmb/ldv00210.1093/bmb/ldv002 ↗
27. 10.1002/9780470571224.pse19610.1002/9780470571224.pse196 ↗
28. L Nnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Phys. 1987;253(1):228–231.
29. 10.1016/j.tca.2005.09.01110.1016/j.tca.2005.09.011 ↗
30. 10.1615/CritRevTherDrugCarrierSyst.v21.i3.1010.1615/CritRevTherDrugCarrierSyst.v21.i3.10 ↗
31. 10.1208/pt06023210.1208/pt060232 ↗
32. 10.1208/s12248-008-9024-910.1208/s12248-008-9024-9 ↗
33. 10.1016/j.ejpb.2015.04.03210.1016/j.ejpb.2015.04.032 ↗
34. Bozkir A, Denli ZF, Basaran B. Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery. Acta Pol Pharm. 2012;69(4):719–724.
35. 10.1016/j.ijpharm.2017.04.01010.1016/j.ijpharm.2017.04.010 ↗
36. 10.1016/S0169-409X(00)00112-510.1016/S0169-409X(00)00112-5 ↗
37. 10.5713/ajas.14.076110.5713/ajas.14.0761 ↗
38. 10.2174/18722105090215081915184110.2174/187221050902150819151841 ↗
39. 10.1016/S0927-7765(99)00105-810.1016/S0927-7765(99)00105-8 ↗
40. 10.1016/j.ejps.2011.06.00710.1016/j.ejps.2011.06.007 ↗
41. 10.1016/j.ejps.2012.04.01310.1016/j.ejps.2012.04.013 ↗
42. 10.1016/j.jconrel.2005.11.01410.1016/j.jconrel.2005.11.014 ↗
43. 10.1016/S0927-7765(00)00148-X10.1016/S0927-7765(00)00148-X ↗
44. 10.1016/S0378-5173(98)00369-X10.1016/S0378-5173(98)00369-X ↗
45. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. The Netherlands: Elsevier B.V; 2000. p. 1–11.
46. Gã Rsoy A, Tã Rkoä Lu M, Senyã Cel B, et al. Evaluation of tableted microspheres of dipyridamole. Drug Dev Commun. 1995;21(4):503–507.